HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) but lowered the price target from $8 to $7.
June 28, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Karyopharm Therapeutics but lowered the price target from $8 to $7.
The maintained Buy rating suggests continued confidence in Karyopharm Therapeutics' prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100